Free shipping on all orders over $ 500

I-BET151

Cat. No. M2096

All AbMole products are for research use only, cannot be used for human consumption.

I-BET151 Structure
Synonym:

GSK1210151A

Size Price Availability Quantity
1mg USD 43 In stock
5mg USD 95 In stock
10mg USD 120 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

I-BET151 (GSK1210151A) is a novel BET bromodomain inhibitor which blocks recruitment of BET to chromatin. GSK1210151A exhibits potent selectivity over an extensive range of diverse protein types such as COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, ion channels and transporters. GSK1210151A displaces BRD3 and BRD4, PAFc and SEC components from chromatin resulting in inhibition of transcription at key genes (BCL2, C-MYC and CDK6) involved in the initiation of mixed lineage leukemia (MLL). GSK1210151A (I-BET151) induces apoptosis and G0/G1 cell cycle arrest in MLL-fusion leukemic cell lines in vitro with IC50 values of 15, 26, 120 and 192 nM for NOMO1, MV4;11, MOLM13 and RS4;11 cell lines respectively. GSK1210151A reduces BCL2 expression in NOMO1 cells. In vivo, GSK1210151A (I-BET151) improves survival and shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine.

Product Citations
Customer Product Validations & Biological Datas
Source Cell Stem Cell (2015). Figure 2. GSK1210151A
Method Efficiently Generating CiNs
Cell Lines TUJ1-stained cells
Concentrations 100 μm
Incubation Time 14 days
Results We found that an additional small molecule, I-BET151, dramatically enhanced the reprogramming rate (with a 90% TUJ1-positive cell yield) and neurite outgrowth of the iNs
Chemical Information
Molecular Weight 415.44
Formula C23H21N5O3
CAS Number 1300031-49-5
Solubility (25°C) DMSO 80 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Seal J, et al. Bioorg Med Chem Lett. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).

[2] Dawson MA, et al. Nature. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Related Epigenetic Reader Domain Products
RVX-208

Apabetalone (RVX-208) is a first-in-class, small molecule inhibitor of BET bromodomain with IC50 of 0.51 μM for BD2.

(+)-JQ1

(+)-JQ1 is a BET bromodomain inhibitor that acts on BRD4(2) with an IC50 of 33 nM and binds to all bromodomain domains in the BET family, but not to bromodomain domains outside the BET family. JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway, and JQ1 down-regulates CD47 expression through a C-MYC-mediated pathway.

I-BET-762

I-BET-762 (GSK525762) is a selective small molecule BET inhibitor.

CPI-0610

CPI-0610 is a novel BET protein bromodomain inhibitor.

OTX015 (Birabresib)

OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4.

  Catalog
Abmole Inhibitor Catalog




Keywords: I-BET151, GSK1210151A supplier, Epigenetic Reader Domain, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.